# MODULE 8 Laboratory Testing



SLMTA Participant's Manual

# **TABLE OF CONTENTS**

NOTE: Print this document single-sided and in color if possible.

Activity: Validation of Test Results	1
Activity: Is the Test Report Ready To Be Released?	3

## **ACTIVITY SUMMARY SHEET**

#### **ACTIVITY** Validation of Test Results

Module 8

#### **PURPOSE:**

The total testing process can be divided into three phases, the pre-analytical phase, the analytical phase, and the post analytical phase. A problem or error in any of the three phases can invalidate the results of the entire testing process. In this activity, participants identify the potential sources of errors or problems and create a checklist to verify patient results before their release.

## This activity supports the following laboratory management tasks and accreditation preparedness checklist items

Management Tasks



- 6.4 Validate new equipment, reagents, and supplies
- 7.3 Enforce good specimen handling and processing practices
- 8.4 Validate assigned tests and specific abnormal results

#### Checklist Items



- 1.1 <u>Laboratory Quality Manual</u> Is there a current laboratory quality manual, composed of the quality management system's policies and procedures, and has the manual content been communicated to and understood and implemented by all staff?
- 1.4 <u>Laboratory Policies and Standard Operating Procedures</u> Are policies and standard operating procedures (SOPs) for laboratory functions current, available and approved by authorized personnel? (Purchasing and Inventory Control, Specimen Storage and Retention, Examination SOPs, Interrupted Services, Examination Validation/Verification, Quality Assurance)
- 6.1 <u>Internal Audits</u> Are internal audits conducted at intervals as defined in the quality manual and do these audits address areas important to patient care?
- 7.14 <u>Product Expiration</u> Are all reagents/test kits in use (and in stock) currently within the manufacturer-assigned expiration dates or within stability?
- 8.1 Are guidelines for patient identification, specimen collection (including client safety), labeling, and transport readily available to persons responsible for primary sample collection?
- 8.2 Are adequate sample receiving procedures in place?
- 8.3 Are specimens stored appropriately prior to testing?
- 8.6 Is complete procedure manual available at the workstation or in the work area?
- 8.7 Is there a reagent logbook for lot number and dates of opening that reflects verification of new lots?
- 8.8 Is each new lot number, new shipment of reagents, or consumables verified before use?
- 8.9 Is internal quality control performed, documented, and verified before releasing patient results?
- 8.11 Are environmental conditions are checked and reviewed accurately?
- 9.1 <u>Test Result Reporting System</u> Are test results legible, technically verified by an authorized person, and confirmed against patient identity?
- 9.2 <u>Testing Personnel</u> Are testing personnel identified on the requisition and record?
- 9.3 <u>Test Result Records</u> Are test results recorded in a logbook or electronic record in a timely manner?
- 9.8 <u>Test Result Report</u> Is the laboratory result report(s) in a standard form determined to be acceptable by its customers?
- 9.9 <u>Test Result</u> Are test results validated, interpreted and released by appropriately-authorized personnel?
- 10.3 Is corrective action performed on all non-conforming aspects of the quality management system documented?




## **KEY MESSAGES**

- The assurance of quality laboratory results relies on a commitment to assess all aspects of the total testing process.
- A problem or error in any of the three phases can invalidate the results of the entire testing process.
- For a QA program to be effective, the necessary policies and procedures must be developed and available to staff members.

### Can you:

- Recognize that a problem or error in any of the three phases can invalidate the results of the whole testing process?
- Identify potential pitfalls at each phase of the total testing process?
- Create a checklist to verify areas before patient results are released?



## **ACTIVITY SUMMARY SHEET**

#### ACTIVITY Is the Test Report Ready To Be Released?

Module 8

#### **PURPOSE:**

Test result reports should be complete, accurate, legible, and clinically valid. In this activity, participants cross-check a test report to identify errors and omissions that must be resolved before the report is released.

# This activity supports the following laboratory management tasks and accreditation preparedness checklist items

Management Tasks



- 8.1 Monitor testing to ensure SOPs are followed and tests are performed and reported properly and promptly
- 8.2 Cross-check test reports against test request to ensure completion of all tests
- 8.3 Review test records and findings promptly to ensure accuracy and timely release of test results
- 8.4 Validate assigned tests and specific abnormal results
- 9.1 Aggregate and report all test findings for each patient

#### Checklist Items



- 1.4 <u>Laboratory Policies and Standard Operating Procedures</u> Are policies and standard operating procedures (SOPs) for laboratory functions current, available and approved by authorized personnel? (Identification and Control of Nonconformities, Quality and Technical Records, Authorization, Reporting of Results)
- 8.14 Are test requests checked with test results, thereby assuring the accuracy and completion of all tests?
- 9.1 <u>Test Result Reporting System</u> Are test results legible, technically verified by an authorized person, and confirmed against patient identity?
- 9.2 <u>Testing Personnel</u> Are testing personnel identified on the requisition and record?
- 9.4 <u>Analytic System/Method Tracing</u> When more than one instrument is in use for the same test, are test results traceable to the equipment used for testing?
- 9.5 Result Cross-check System Is there a system for reviewing for transcription errors?
- 9.8 <u>Test Result Report</u> Is the laboratory result report(s) in a standard form determined to be acceptable by its customers?
- P.9 Test Result Are test results validated, interpreted and released by appropriately-authorized personnel?
- 10.3 Is corrective action performed on all non-conforming aspects of the quality management system documented?



#### **KEY MESSAGES**

- A cross-check provides a quality step to review accuracy and reliability of results prior to release.
- Each test request should have a corresponding result that is accurate and clinically meaningful.
- Laboratory errors and omissions are best handled prior to their release from the laboratory. However the most efficient way to handle errors is to prevent their initial occurrence.

#### Can you:

- Cross-check a laboratory report identifying errors and omissions?
- Provide next steps to resolve or prevent the errors or omissions?

SELF-ASSESSMENT

For this activity, you will need:
Handout: Errors Noted (801)
☐ Worksheet 1: Laboratory Report (802)
☐ Worksheet 2: Report for Review (803)
Job Aid: Cross-checking Guidelines (804)

# Errors Noted<sup>801</sup>

Laboratory		1		5-10-2	1500	Collec	ted Date/7	Time: 3-10-	2005 00	
		Hematology		Additional In-House Testing						
⟨] CBC		00	Tech initials	Tech initials:	Ar	η		Normal Value		
Results		Adult No	rmal Values	: SL	Urine Pregnancy		OS	NEG	N/A	
15,3	WBC	м 3.3 - 10.0	F 3.4 – 9.8	x10³/ul	[]CRP	PC	OS	NEG	NEG	
94	RBC	4.35 - 5.9	3.69 - 5.13	x10 <sup>6</sup> /ul	[ ] Malaria Rapid		OS	NEG	NEG	
11.0	HGB	13.7 - 16.7	11.7 - 14.5	g/dl		EAK CTIVE	REACTIV	NON REACTIVE	NON REACTIV	
12.0	HCT	40.5 - 49.7	34.1 – 44.3	%	[]KOH			Source:		
68.9	MCV	79.7 – 92.0	81.5 – 96.7	fl	[ ] Saline Prep					
22.6	МСН	26.1 - 33.3	26.5 – 33.5	pg	[ ] Gram Stain					
31.0	MCHC	32.2 – 35.0	31.9 – 35.3	g/dl						
.60	RDW	11.6	- 14.4	%						
122	PLT	140	- 440	x10³/ul		(	CCMS Uri	inalysis		
Differential	Tech in	itials:	Adult Non	mal Values	ĭ⊠ Tech	initials:	AM	7 No	ormal Values	
85	Neutrophils		45 -	66%	yellow		Color		N/A	
10	Bands (Neutr	ophilic)	1-	12%	hazy	, Am			N/A	
7/	Lymphocytes		20 -	40%	16		Urobilinoge		<16 umol/L	
	Atypical Lym	phocytes	0 - 2% 4 - 10% 1 - 6%		meg		Glucose		Negative (mmol/L) Negative (ummol/L) Negative (mmol/L) 1.005 – 1.030	
	Monocytes						Bilirubin			
	Eosinophils				neg		Ketones			
	Basophils		0-2%		(1.05		Specific Gra	ivity 1.		
	Other				moderate Blood			Negative		
BC Morpholo	1	[ ] Normal N	Morphology		(65)	)	pH	NI.	5.0 – 8.0 Negative (g/L)	
		cytosis	Morphology Terms		10		Protein	180	Negative (g/L)	
		Microcytosis	1 - 61:-14		(+)		Leukocytes		Negative	
+2		Macrocytosis	2 = Moderate		moderate			n initials:	regative	
Hypochromia			3 = Marke	[A] Microscopia			stals:			
	Poikli	ocytosis				-				
		Chemistry			10-20	RBC/H				
] Basic [ ]Con	nprehensive		Lipid To	ech initials		EPI-rena EPI-	I/HPF Casts	LPF;		
R		rmal I / F)	Result	Normal (M / F)	5-10	squamo /HPF	ous			
LCLUC	(	3.9 – 5.8 [XAI	T (281	< 41 / < 31		Bacter	ria Triche	omonas / Yeast / Pa	rasite:	
] GLUC		2.5. 6.4	10001	< 37 / < 31				omonus / Touse / Tu		
JUREA 4	9)	mmol/L [] AS	ST	U/L		Mucu	S			
] Na		136 - 145 mmol/L [ ] AI	P	53 – 128 / 42 – 98 U/L		Q	uality Ass	surance		
] K	3 5 _ 5 3 38 _ 171 / Date Ordering							Smith		
] CI	1	98 - 110 mmol/L [] LE	DН	230 – 460 U/L		[ ] Stat		[ Fasting [ ]	Non-Fasting	
CREAT 4	18 62-11	5 / 53 -97 umol/L [] AN 208-430		27 – 102 U/L 2.15 – 2.50						
] URIC ACID ] T- PROT		360 umol/L A CA	ALCIUM HOS	0.87-1.45	Doctor Signature:					
1 ALBUMIN		5 – 52 g/L [] CI		3.6 – 5.7 mmol/L	3.6-5.7 Patient Information					
T-BILI	And the same of th	5.1 – 20.5 umol/L [] TF	RIG	< 2.26 mmol/L	Name (surname, fir	st):				
D-BILI	0.0	3.4 umol/I [ ] HI	0.	0.78 – 1.94 / 85–2.38 mmol/L < 1.71 – 5.44 /	D.O.B.:/_		Age:	[]	Male [] Fem	
] GGT	- 55 /	< 38 U/L [ ] ca LDL-		< 1./1 – 5.44 / .48–5.80 mmol/L	Patient No.:					

# Laboratory Report<sup>802</sup>

Laboratory	Y	R	eport Da	ite/Time:	5-10-20	1500		vn by: ected [		: 3-10-	2008 01	
	/500 Collected Date/Time: 3-10-2008 O  Additional In-House Testing											
[x] CBC		Hemat		Tech initials	Tech initials:		Normal Valu					
Results	Adult 1			d Values	Urine Pregnancy		POS		NEG	N/A		
15,3	WBC M 3.3 - 10.0		10.0	<sup>™</sup> 3.4 – 9.8 x10³/ul		[]CRP		POS		NEG	NEG	
94	RBC	C 4.35	- 5.9	3.69 - 5.13	x106/ul	[ ] Malaria Rapid		POS		NEG	NEG	
11.0	HGI	В 13.7	- 16.7	11.7 – 14.5	g/dl		VEAK ACTIVE	RE	EACTIVE	NON REACTIVE	NON REACTI	
22.0	HC'	Т 40.5	- 49.7	34.1 - 44.3	%	[]KOH				urce:		
689	MC'	V 79.7	- 92.0	81.5 - 96.7	fl	[ ] Saline Prep						
22.6	MCI	Н 26.1	- 33.3	26.5 - 33.5	pg	[ ] Gram Stain						
31,0	MCF	HC 32.2	- 35.0	31.9 - 35.3	g/dl							
.60	RDV	W	11.6 - 1	4.4	%							
122	PLT	Γ	140 - 44	40	x10³/ul			CCM	S Urinaly	sis		
Differential	Te	ech initials:		Adult Nor	mal Values	ĭ Tech	initia	ls:	7m	Nor	rmal Values	
85	Neutro	phils		45 – 66%		yellow	-	Colo	ЭГ		N/A	
10	Bands	(Neutrophilic)		1 – 12%		hazy		Appearance			N/A	
7	Lymph				40%	16			oilinogen	_	16 umol/L	
		al Lymphocytes			2%	Mory		Gluc			tive (mmol/L)	
Monocytes			4-10%			neg			ubin		Negative (ummol/I	
	Eosinophils			1-	neg		Keto			Negative (mmol/L)		
	Basophils			0 -	2%	V M M					005 – 1.030	
Other					<u> </u>	moderate Blood		bd	Negative			
RBC Morphology [] Norma			Normal Mor	phology		65 pH			ain	5.0 – 8.0 Negative (g/L)		
Anisocytosis  Microcytosis			eie	Morpholog	1.0			Protein Nitrite		Negative (g/L)		
+2	-			1 = Slight		(+)			ukocytes		Negative	
+1		Macrocytosis Hypochromia		2 = Moderate 3 = Marked		moderate Microscopic  WBG		Leur	Tech init		regative	
								BC/HPF Crystals:				
		Poikliocytosis Chem	victus.			10 20	DDC	C/HPF				
[ ] Basic [ ]Cor	nprehensi			id T	ech initials	10-20	-	enal/HPF	Casts/LPF:			
[ ] Dasic [ ] Cor	приспеня	Normal	Licip		Normal		EP		Cubbility.			
F	Result	(M / F)		Result	(M / F)	5-10	squa /HP	amous F				
] GLUC		3.9 – 5.8	[XALT	30.1	< 41 / < 31			cteria	Trichomona	s / Yeast / Par	asite:	
/		mmol/l -fasting 2.5 - 6.4		300	< 37 / < 31		N/-					
UREA 4	9	mmol/L	[]AST		U/L		Mi	icus				
] Na		136 - 145 mmol/L	[] ALP		53 – 128 / 42 – 98 U/L			Qualit	ty Assura	nce		
35_53			[ ] CK		Date Requested: 3/10/08 Ordering Doctor: Smith							
] CI		98 - 110	[]LDH		230 – 460 U/L	E d Doutino	F 1 C	tot []]		Fasting []N	lon Fastino	
	18	mmol/L 62–115 / 53 -97 umol/L	[ ] AMY		27 – 102 U/L	QA Review:	[12	iai []w	vaiting [%]	asting []F	von-rasting	
] URIC ACID		208-430 155 - 360 umol/		CIUM	2.15 – 2.50 mmol/L	Date:/		Comments	s:			
] T- PROT		64 - 83 g/L	[ PHOS		0.87-1.45 mmol/L	Doctor Signature:						
] ALBUMIN (	(C) 35 – 52 g/L [] CHOL 3.6 – 5.7 mmol/L							Patient	t Informa	tion		
<b>√</b> T-BILI	-	5.1 – 20.5 umol/L	[]TRIG		< 2.26 mmol/L	Name (surname, fi	rst):					
XI I-DILL		0.0 – 3.4 umol/	[]HDL-	C 0.	0.78 – 1.94 / 85–2.38 mmol/L		-	A	.ge:	[]M	//ale []Fem	
✓ D-BILI					< 1.71 - 5.44 /							
		< 55 / < 38 U/L	[ ] calc LDL-C	1.	48–5.80 mmol/L	Patient No.:						

# Report for Review<sup>803</sup>

Cape Regi	onal 1 <sub>5</sub>	mear	(	critical pl	Fied by 1	- Dr Smith	Lab #: Drawn	32 by: SL				
Laborator	y	Re	eport D	ate/Time:						3-10-20	08 0815	
		10 5.000	Collected Date/Time: 3-10-2008 08/5  Additional In-House Testing									
CBC		Hemato		Tech initials	: SL	Tech initials:	An	n		_	Normal Values	
Results		A	Adult Norm	nal Values		Urine Pregnancy	PC	OS		NEG	N/A	
15.3	WBC	м 3.3 -	10.0	F 3.4 – 9.8	x10 <sup>3</sup> /ul	[]CRP	] CRP POS			NEG	NEG	
3,96	RBC	4.35	- 5.9	3.69 - 5.13	x10 <sup>6</sup> /ul	[ ] Malaria Rapid	PC	OS		NEG NEG		
11,0	HGB	13.7 -	16.7	11.7 – 14.5	g/dl		EAK	REACT	TVE R	NON REACTIVE	NON REACTIVE	
33.0	HCT	40.5 -	49.7	34.1 – 44.3	%	[]KOH		10010	Sour			
108.9	MCV	79.7 -	- 92.0	81.5 – 96.7	fl	[ ] Saline Prep						
22.6	MCH	26.1 -	- 33.3	26.5 – 33.5	pg	[ ] Gram Stain						
31,0	MCHC	32.2 -	- 35.0	31.9 – 35.3	g/dl							
16,0	RDW		11.6 -	14.4	%							
22	PLT (	(22)	140 -	440	x10³/ul		(	CCMS U	rinalys	sis		
Differential	Tech	initials: (	5-W	Adult Norr	nal Values	Tech i	nitials:	Am	)	No	mal Values	
85	Neutrophil	S		45 –	66%	vellow		Color			N/A	
10	Bands (Ne	itrophilic)		1 – 1	12%	hazy		Appearan	ice		N/A	
5	Lymphocy	tes		20 –	40%	16		Urobilino	gen	<	6 umol/L	
	Atypical L	ymphocytes		0 –	2%	negati	ve	Glucose		Negative (mmol/L)		
	Monocytes			4 – 1	10%	negative Bilirubin				Negative (ummol/L)		
	Eosinophil	S		1 –	6%	negative Ketones				Negative (mmol/L)		
	Basophils			0 -	10025 Specific Gr			Gravity	ravity 1.005 – 1.030			
	Other					moderate Blood				Negative		
RBC Morpholo			Normal Mo	rphology		6.5 pH				5.0 - 8.0		
+1	An	socytosis		Morpholog	y Terms	1. O Protein				Negative (g/L)		
+2	+ 2 Microcytos					positive Nitrite			-	Negative		
	- 11-	Macrocyto	sis	1 = Slight 2 = Moderate			moderate Leukocy				Negative	
+1	Hy	oochromia		3 = Marke	ed .	Microscopic  WBC/HP		Tech initials: Am			m	
	Poi	kliocytosis				5-10						
		Chem		1.22		10-20	RBC/HI					
[ ] Basic [ ]Co	mprehensive	[ ] LFT	[ ] Li	ipid Te	ech initials		EPI-rena EPI-	l/HPF Ca:	sts/LPF:			
	Docult	Normal (M / F)	,	Result	Normal & V (M / F)	3-5	squamo /HPF	ous				
[]GLUC	mn	3.9 – 5.8 ol/l -fasting	[A] ALT	30	< 41 / < 31 U/L	moderate	Bacter	ria Tri	chomonas	/ Yeast / Para	nsite:	
WUREA 1	1.9	2.5 – 6.4 mmol/L	[]AST		< 37 / < 31 U/L		Mucus	5				
[ ] Na		136 - 145 mmol/L	[]ALP		53 – 128 / 42 – 98 U/L	Quality Assurance						
[ ]K		3.5 – 5.3 mmol/L	[]CK		38 – 171 / 26 – 145 U/L							
[]CI		98 - 110 mmol/L	[]LDH		230 – 460 U/L	[ Nouties	[ ] Ctot	[ ] Waitin		•	Ion Faction	
CREAT 41	8 62-	115 / 53 -97 umol/L	[]AMY	(	27 – 102 U/L	02 QA Review:						
[ ] URIC ACID	155	208– 430 - 360 umol/I	[ CAL	CIUM 2.3	O 2.15 – 2.50 mmol/L							
[ ] T- PROT		64 – 83 g/L	[X] PHO		0.97 1.45	Doctor Signature: _						
[ ] ALBUMIN							Pa	tient In	format	ion		
MT-BILI	0.0	5.1 – 20.5 umol/L	[]TRIC	3	< 2.26 mmol/L	Name (surname, firs	t):					
[¾D-BILI C	5 0.0	- 3.4 umol/L		-C 0.8	0.78 – 1.94 / 35–2.38 mmol/L	D.O.B.:/_		Age:		[ ] M	lale [] Female	
[]GGT	< 5:	5 / < 38 U/L	[ ] calc LDL-C	1.4	< 1.71 – 5.44 / 48–5.80 mmol/L	Patient No.:						
[ ] Glucose Result by Glucometer	mm	4.1 – 5.9 ol/l -fasting				Diagnosis:						

## Cross-Checking Guidelines<sup>804</sup>

## Items to be verified prior to release of test results

#### Completeness

- Each test has a corresponding result
- Patient information
- Clinical information
- Provider information
- Specimen information
- Collection information
- Initials of staff member who performed each test indicated
- Date and time of report
- Result information identical with log book

#### Critical (Panic Values)

- Result verified and verification documented
- Documentation of result notification
  - o On result report
  - o In log book

### **Testing Priority**

- STAT request's communicated and documented
- Delays communicated and documented

#### **Specimen Rejection**

- Reason for specimen rejection documented
- Clinician and / or patient notified and this notification is documented

#### **Result Information**

- Legible
- Proper placement of decimals
- Uniform result alignment with regards to decimal placement
- Format of results corresponds with SOP
- Proper units and significant places
- Abbreviations used from approved list
- Within instrument linearity
- No associated instrument codes with regard to accuracy
- Result corresponds with correct test
- Diluted results multiplied with correct dilution factor
- No consistent pattern or trend exhibited between patients for a specific analyte during cross-checking unless patient grouping under review is from the same diagnosis/population pool (i.e. Newborn hemoglobin and hematocrit)

#### **Appropriateness**

- Test relevant to patient's age and gender
- Result information makes clinical sense
  - Electrolytes
  - o BUN/Creatinine
  - Macroscopic with microscopic
  - Instrument with smear
  - RBC Indices, RBC count, Hemoglobin and Hematocrit all show agreement